Form D · Biotechnology
Myris Therapeutics, Inc.
Sharpsburg, PA · CIK 0001924725
Offering snapshot reported Oct 14, 2026 · SEC filing
- Reported sold
- $500K Offering amount: $4.5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 1, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 14, 2026 | Initial | $500,000 | No comparison | 4 | SEC filing |
| Apr 29, 2022 | Initial | $1,549,991 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-601204
Convertible Promissory Notes
Source: Form D, filed Oct 14, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Patrick Bailey | Executive |
| Laura E. Benjamin | Director, Executive |
| David N. Colaizzi | Director |
| Barbara S. Fox | Director |
| Autumn Gindlesberger | Executive |
| Krzysztof Matyjaszewski | Director |
| Mark A. Murcko | Director |
| Jean Pineault | Director, Executive |
| Alan Russell | Promoter |
| Antonina Simakova | Executive |
| Rebecca Wolfe | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
307 23 Rd St. Ext Suite 150
Sharpsburg, PA, 15215
Phone: 412-816-5315
Sharpsburg, PA, 15215
Phone: 412-816-5315